Successful comeback of the single-dose live oral cholera vaccine CVD 103-HgR

被引:16
|
作者
Herzog, Christian [1 ]
机构
[1] Swiss Trop & Publ Hlth Inst, Dept Med, Socinstr 57, CH-4051 Basel, Switzerland
关键词
Cholera; Oral live vaccine; CVD; 103-HgR; Single-dose; DOUBLE-BLIND; EFFICACY; TRIAL; IMMUNOGENICITY; SAFETY; TY21A;
D O I
10.1016/j.tmaid.2016.07.003
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Effective and easy to administer cholera vaccines are in need more than ever, for at risk populations and travellers alike. In many parts of the world cholera is still endemic, causing outbreaks and constituting repeatedly serious public health problems. The oral live cholera vaccine CVD 103-HgR (Orochol, Mutachol), the first genetically modified organism (GMO) used as vaccine, was in its time (launched 1993, Switzerland) the ideal cholera vaccine: single-dose, protective efficacy of 80-100% against moderate to severe cholera, acting within 8 days and exhibiting excellent safety, indiscernible from placebo. However, there were strong headwinds: In the 1990s the indication for cholera vaccines was generally downplayed by experts and in 1997 the European Commission called for a moratorium of GMOs which blocked the registration in the European Union. Thus, demand for this vaccine remained low and in 2003 it was taken off the market for economic reasons. After a decade in obscurity it (Vaxchora) has resurfaced again, now produced in the U.S. and equipped with a U.S. FDA license (June 10, 2016). What had happened? This commentary gives a critical account of an almost unbelievable string of misadventures, emerging adverse circumstances and man-made failures which nearly killed this single-dose live oral cholera vaccine. The good news is that patience and persistence lead to success in the end, allowing good science to prevail for the benefit of those in need. (C) 2016 Elsevier Ltd. All rights reserved.
引用
收藏
页码:373 / 377
页数:5
相关论文
共 50 条
  • [31] SAFETY AND IMMUNOGENICITY IN NORTH AMERICANS OF A SINGLE DOSE OF LIVE ORAL CHOLERA VACCINE CVD 103-HGR - RESULTS OF A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND CROSSOVER TRIAL
    KOTLOFF, KL
    WASSERMAN, SS
    ODONNELL, S
    LOSONSKY, GA
    CRYZ, SJ
    LEVINE, MM
    [J]. INFECTION AND IMMUNITY, 1992, 60 (10) : 4430 - 4432
  • [32] Long-Term Immunogenicity of Live Oral Cholera Vaccine CVD 103-HgR in Adolescents Aged 12-17 Years in the United States
    McCarty, James M.
    Cassie, David
    Bedell, Lisa
    Lock, Michael D.
    Bennett, Sean
    [J]. AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2021, 104 (05): : 1758 - 1760
  • [33] Pre-existing Helicobacter pylori serum IgG enhances the vibriocidal antibody response to CVD 103-HgR live oral cholera vaccine in Malian adults
    Khitam Muhsen
    Samba O. Sow
    Milagritos D. Tapia
    Fadima C. Haidara
    Mardi Reymann
    Valeria Asato
    Wilbur H. Chen
    Marcela F. Pasetti
    Myron M. Levine
    [J]. Scientific Reports, 10
  • [34] Further molecular characterization and stability of the live oral attenuated cholera vaccine strain CVD103-HgR
    Favre, D
    Struck, MM
    Cryz, SJ
    Viret, JF
    [J]. VACCINE, 1996, 14 (06) : 526 - 531
  • [35] SAFETY AND IMMUNOGENICITY OF A BOOSTER DOSE OF VIBRIO-CHOLERAE CVD-103-HGR LIVE ORAL CHOLERA VACCINE IN SWISS ADULTS
    CRYZ, SJ
    LEVINE, MM
    LOSONSKY, G
    KAPER, JB
    ALTHAUS, B
    [J]. INFECTION AND IMMUNITY, 1992, 60 (09) : 3916 - 3917
  • [36] Pre-existing Helicobacter pylori serum IgG enhances the vibriocidal antibody response to CVD 103-HgR live oral cholera vaccine in Malian adults
    Muhsen, Khitam
    Sow, Samba O.
    Tapia, Milagritos D.
    Haidara, Fadima C.
    Reymann, Mardi
    Asato, Valeria
    Chen, Wilbur H.
    Pasetti, Marcela F.
    Levine, Myron M.
    [J]. SCIENTIFIC REPORTS, 2020, 10 (01)
  • [37] SAFETY, IMMUNOGENICITY, AND EFFICACY OF RECOMBINANT LIVE ORAL CHOLERA VACCINES, CVD-103 AND CVD-103-HGR
    LEVINE, MM
    HERRINGTON, D
    LOSONSKY, G
    TALL, B
    KAPER, JB
    KETLEY, J
    TACKET, CO
    CRYZ, S
    [J]. LANCET, 1988, 2 (8609): : 468 - 470
  • [38] SAFETY, IMMUNOGENICITY, AND TRANSMISSIBILITY OF SINGLE-DOSE LIVE ORAL CHOLERA VACCINE STRAIN CVD-103-HGR IN 24-MONTH-OLD TO 59-MONTH-OLD INDONESIAN CHILDREN
    SIMANJUNTAK, CH
    OHANLEY, P
    PUNJABI, NH
    NORIEGA, F
    PAZZAGLIA, G
    DYKSTRA, P
    KAY, B
    SUHARYONO
    BUDIARSO, A
    RIFAI, AR
    WASSERMAN, SS
    LOSONSKY, G
    KAPER, J
    CRYZ, S
    LEVINE, MM
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1993, 168 (05): : 1169 - 1176
  • [39] Age-Dependent Association among Helicobacter pylori Infection, Serum Pepsinogen Levels and Immune Response of Children to Live Oral Cholera Vaccine CVD 103-HgR
    Muhsen, Khitam
    Lagos, Rosanna
    Reymann, Mardi K.
    Graham, David Y.
    Pasetti, Marcela F.
    Levine, Myron M.
    [J]. PLOS ONE, 2014, 9 (01):
  • [40] POTENTIAL FOR REACQUISITION OF CHOLERA ENTEROTOXIN GENES BY ATTENUATED VIBRIO-CHOLERAE VACCINE STRAIN CVD 103-HGR
    KAPER, JB
    MICHALSKI, J
    KETLEY, JM
    LEVINE, MM
    [J]. INFECTION AND IMMUNITY, 1994, 62 (04) : 1480 - 1483